PRESS RELEASE

2009 Net Sales

Villepinte, 11 February 2010

Consolidated Group revenue (IFRS)

In thousands of euros	2009	2008	Change
First quarter	79,031	75,573	+4.6%
Second quarter	83,485	81,376	+2.6%
Third quarter	81,997	79,160	+3.6%
Fourth quarter	90,966	84,674	+7.2%
TOTAL…………….......…………………..	**335,479**	**320,783**	**+4.6%**

Consolidated revenue by region

In thousands of euros	2009	2008	Change
European subsidiaries	259,193	251,912	+2.9%
Other markets	76,286	68,872	+10.8%
TOTAL……………........………………..	**335,479**	**320,783**	**+4.6%**

Robust revenue growth in the fourth quarter (+7.2%)

Dotarem, Guerbet's flagship product in magnetic resonance imaging (MRI) delivered another good performance. In line with trends over the full year, Dotarem maintained its growth momentum in the fourth quarter in all markets where it is sold, particularly in France and Germany.

For the full year and worldwide, Dotarem's sales grew 9.5% (+17.2% in volume).

In the x-ray imaging segment, **Xenetix** sales accelerated in the year's final quarter, driven by growth in "Other markets" consisting notably of Brazil, China and other Asian countries.

In this region and for the full year, Xenetix sales expanded 22.8% while in Europe remained largely stable.

For all regions combined, Xenetix sales grew 4.9% in 2009 (+21.6% in volume).

Overall, Guerbet's consolidated revenue in 2009 grew 4.6%, sustained by further market share gains, the addition of new accounts and expanded geographical coverage for the Group's products in a highly competitive environment.

Efforts to strengthen R&D were accompanied by increased expenditures. These included the launch of clinical phases of the programme for Dotarem's filing in the US and the continued development of new chemical entities.

The combined effect of these developments and industrial production cost trends will contribute to lower current operating income compared to 2008 while the net margin is expected to marginally exceed 6%.

The capital spending programme has continued with the progressive commissioning of new facilities in France in Lanester, Marans and Gonesse. These investments were pursued adversely affecting debt that remained stable in relation to 31 December 2008

A complete presentation of Group results for fiscal 2009 with comments will be published on 2 March 2010.

Contact: Finance Department. Tel: +33 (0)1 45 91 50 11